Prosetin

Prosetin is a clinical-stage biotechnology company dedicated to developing the first-ever MAP4K inhibitor for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company was founded as a collaboration between Project ALS and researchers at Columbia University to advance a lead candidate, also named Prosetin, which was specifically designed to cross the blood-brain barrier and target neuroinflammation and motor neuron death. Prosetin represents a unique model of drug development, emerging from a non-profit/academic partnership to address the urgent need for effective ALS therapies. The company's primary focus is on completing clinical trials to demonstrate the safety and efficacy of its lead small molecule in ALS patients.